The role of KRAS SNP rs61764370 and p53 expression in preeclampsia pathophysiology among pregnant women

M. K. Sultan; M. E. Al-Gazally; B. J. Al-Rubayae

doi:10.15421/0225027

M. K. Sultan University of Babylon
M. E. Al-Gazally University of Al-Ameed
B. J. Al-Rubayae University of Babylon

Keywords: preeclampsia, KRAS SNP rs61764370, p53 gene expression, pregnancy complications.

Abstract

We examined the relationship between p53 gene expression levels and the KRAS single nucleotide polymorphism (SNP) rs61764370 in pregnant women. From January 23, 2024 until June 13, 2024, Babylon Teaching Hospital for M a ternity and Children carried out a case-control research. There were 130 participants in all, 65 of whom had been dia g nosed with third-trimester preeclampsia and 65 of whom were healthy controls. Blood samples were obtained for quantit a tive real-time PCR (qRT-PCR) evaluation of p53 gene expression and KRAS SNP analysis. Distribution of T/G SNPs in KRAS . Both groups had a high prevalence of the TT genotype, and the distribution of genotypes did not differ statistically significantly between the groups. TP53 gene expression. The sick group's p53 expression levels were noticeably higher than those of the controls, suggesting that p53 may play a part in the pathophysiology of preeclampsia. Compared to co n trols, patients had a considerably larger median fold change in p53 expression. These results suggest that p53 overexpre s sion might play a crucial role in the pathophysiological mechanisms underlying preeclampsia, potentially by promoting oxidative stress and endothelial dysfunction. More research on these features is necessary since the lack of a significant association with the KRAS SNP raises the possibility that preeclampsia is driven by other genetic or environmental v a riables.

References

Abdul-Mohaymen, N., Al-Obaidi, A. B., & Rasheed, T. (2011). High expression of P53 protein in recurrent pregnancy loss could play a role in the pathology! Journal of the Faculty of Medicine Baghdad, 53(2), 194–197.

Al-Gazally, M. E., Al-Awad, A. S., & Kzar, H. H. (2016a). Evaluating the superoxide dismutase-1 status in wild type and mutant at codons 12 and 13 of KRAS gene spectrum for the patients with sporadic colorectal cancer. International Journal of PharmTech Research, 9(3), 272–279.

Al-Gazally, M. E., Al-Awad, A. S., & Kzar, H. H. (2016b). Assessment of antioxidant status in different genotypes/phenotypes at codon 72 of TP53 gene for patients with sporadic colorectal cancer in Babylon Province. International Journal of PharmTech Research, 9(3), 280–286.

Al-Haddad, R. H., Jasim, H. M., & Saleh, W. A. (2020). Lack of association between LCS6 variant in KRAS gene with the occurrence of breast tumors in Iraqi women. Baghdad Science Journal, 17(2), 426–430.

Bisson, C., Dautel, S., Patel, E., Suresh, S., Dauer, P., & Rana, S. (2023). Preeclampsia pathophysiology and adverse outcomes during pregnancy and postpartum. Frontiers in Medicine, 10, 1144170.

Bong, I., Lim, P., Balraj, P., Sim Ui Hang, E., & Zakaria, Z. (2006). Quantitative analysis of the expression of p53 gene in colorectal carcinoma by using real-time PCR. Tropical Biomedicine, 23(1), 53–59.

Burton, G. J., Redman, C. W., Roberts, J. M., & Moffett, A. (2019). Pre-eclampsia: Pathophysiology and clinical implications. British Medical Journal, 366, l2381.

Ferretti, C., Bruni, L., Dangles-Marie, V., Pecking, A. P., & Bellet, D. (2007). Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Human Reproduction Update, 13(2), 121–141.

Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R. (2020). Immune modulatory effects of oncogenic KRAS in cancer. Nature Communications, 11(1), 5439.

Ives, C. W., Sinkey, R., Rajapreyar, I., Tita, A. T. N., & Oparil, S. (2020). Preeclampsia – pathophysiology and clinical presentations: JACC state-of-the-art review. Journal of the American College of Cardiology, 76(14), 1690–1702.

Jaiswal, S. K., Raj, S., & DePamphilis, M. L. (2021). Developmental acquisition of p53 functions. Genes, 12(11), 1675.

Jancík, S., Drábek, J., Radzioch, D., & Hajdúch, M. (2010). Clinical relevance of KRAS in human cancers. Journal of Biomedicine and Biotechnology, 2010, 150960.

László, L., Kurilla, A., Takács, T., Kudlik, G., Koprivanacz, K., Buday, L., & Vas, V. (2021). Recent updates on the significance of KRAS mutations in colorectal cancer biology. Cells, 10(3), 667.

Moulder, D. E., Hatoum, D., Tay, E., Lin, Y., & McGowan, E. M. (2018). The roles of p53 in mitochondrial dynamics and cancer metabolism: The pendulum between survival and death in breast cancer? Cancers, 10(6), 189.

Olcum, M., Tufekci, K. U., & Genc, S. (2022). MicroRNAs in genetic etiology of human diseases. Methods in Molecular Biology, 2257, 255–268.

Sharp, A. N., Heazell, A. E., Baczyk, D., Dunk, C. E., Lacey, H. A., Jones, C. J., Perkins, J. E., Kingdom, J. C., Baker, P. N., & Crocker, I. P. (2014). Preeclampsia is associated with alterations in the p53-pathway in villous trophoblast. PloS One, 9(1), e87621.

Weber, S. M., & Carroll, S. L. (2021). The role of r-ras proteins in normal and pathologic migration and morphologic change. The American Journal of Pathology, 191(9), 1499–1510.

Zhao, Y., Zhao, G., & Li, W. (2022). MicroRNA-495 suppresses pre-eclampsia via activation of p53/PUMA axis. Cell Death Discovery, 8(1), 132.